

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

RESULTS ESTIMATE OF DONG-E-E-JIAO FOR THE YEAR ENDED 31 DECEMBER 2024

On 17 January 2025, Dong-E-E-Jiao released its results estimate for the year ended 31 December 2024.

Dong-E-E-Jiao Company Limited (東阿阿膠股份有限公司) (“**Dong-E-E-Jiao**”) is a company incorporated in the People’s Republic of China. The shares of Dong-E-E-Jiao are listed on the Shenzhen Stock Exchange. As of the date of this announcement, Dong-E-E-Jiao is directly held as to 9.99% of its equity interests by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) and approximately 23.50% is held by the Company through its non-wholly owned subsidiary, China Resources Dong-E-E-Jiao Company Limited (華潤東阿阿膠有限公司). The Group effectively controls approximately 23.30% of Dong-E-E-Jiao. Dong-E-E-Jiao is accounted for as a subsidiary of the Company.

On 17 January 2025, Dong-E-E-Jiao released its results estimate for the year ended 31 December 2024, in which, it announced that the net profit attributable to the shareholders of Dong-E-E-Jiao for the year ended 31 December 2024 is estimated to range from approximately RMB1,500 million to RMB1,600 million (as compared to the same period last year of net profit of approximately RMB1,150.8786 million), net profit excluding non-recurring gain or loss is estimated to range from approximately RMB1,400 million to RMB1,500 million (as compared to the same period last year of net profit of approximately RMB1,082.6285 million), and basic earnings per share is estimated to range from approximately RMB2.33 per share to approximately RMB2.49 per share (as compared to same period last year of profit per share of approximately RMB1.79 per share) (the “**Dong-E-E-Jiao Results Estimate**”).

The main reasons for the change in results are set forth as follows:

In 2024, Dong-E-E-Jiao closely focused on the theme of “growth and quality”, firmly implemented the “1238” development strategy and continued to deeply practise “reshaping values, businesses, organisation and ethos” and achieved steady growth in operating performance. It adheres to a consumer-centric approach, further enhance the brand’s market awareness and influence through the deep combination of high-potential nodes and media, multi-dimensional digital integrated marketing and innovative channel communication. It continues to firmly implement the “dual growth model” driven by both pharmaceuticals and health consumer products, consolidate the value leadership of Dong-E-E-Jiao block in the whole system, create a large variety strategy of compound E-Jiao syrup in the whole industry chain, expand the “Taohuajie” as the top brand for nourishing energy and beauty in all regions, innovate the product and effect synergy of E-Jiao instant powder in all directions, layout the “Royal Weichang 1619” men’s nourishing product matrix in all dimensions and focus on opening up a new track for “Zhuangben” cistanche deserticola category at full speed.

In 2025, Dong-E-E-Jiao will focus on “growth and breakthrough” in its principal businesses and deepens the coordinated development of the “three-industry integration” of the gelatin industry chain. Dong-E-E-Jiao will continue to strengthen, optimize and expand its core business, accurately expand its cornerstone business, coordinate the development of potential products, focus on cultivating extended varieties and systematically promote the implementation of the “one center and three highlands” research and development platform. With innovation-driven and lean operations as the core, Dong-E-E-Jiao will enhance digital capabilities around products and services, gather new-era and new-quality productivity, strive to promote steady and high-quality growth in performance and strive to become the most trusted leader in nourishment and health for the general public.

The Dong-E-E-Jiao Results Estimate was prepared in accordance with the PRC Generally Accepted Accounting Principles and has not been audited or reviewed. For details of the financial data, those to be disclosed in the annual report for the year ended 31 December 2024 to be issued by Dong-E-E-Jiao shall prevail.

The financial information in this announcement is limited to Dong-E-E-Jiao only and does not represent or provide a complete view of the operational or financial status of the Group.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 17 January 2025

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Tao Ran and Mdm. Deng Rong as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors; and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.